Dapiglutide is a first-in-class peptide with dual activity on the GLP-1 and GLP-2 receptors and with potential to treat several metabolic/gastrointestinal (GI) diseases. In a multiple ascending dose cohort trial, 40 healthy subjects (mean BMI 24.6 kg/m2) received once weekly s.c. injections of dapiglutide (1, 2.25, 3.5 or 6 mg) or placebo for 4 weeks. There were no serious or severe adverse events (AEs) and no withdrawals. The most frequent related AEs reported were GI disorders and metabolism and nutrition disorders similar to marketed GLP-1RAs. No subject developed anti-drug antibodies. The pharmacokinetics (PK) showed dose proportionality with a low inter-subject variability and a mean half-life of 123-129 hours across the 4 dose cohorts. Dose-response was shown for plasma glucose, insulin, triglycerides, and gastric emptying after a mixed meal test. Mean body weight loss was 0.1%, 0.5%, 2.4% and 4.5% after 4 weeks of treatment in each cohort (fig 1) . Multiple doses of dapiglutide were well-tolerated and the safety profile is similar to GLP-1 and GLP-2 receptor agonists. The PK results support that dapiglutide is suitable for once-weekly dosing. The clinical potential of dapiglutide as a novel treatment for obesity and NASH should be explored in trials of longer duration.


M.B.Olsen: Employee; Zealand Pharma A/S, Stock/Shareholder; Novo Nordisk A/S, Zealand Pharma A/S. U.Hövelmann: None. J.Griffin: Employee; Zealand Pharma A/S, Stock/Shareholder; Zealand Pharma A/S. K.M.Knudsen: Employee; Zealand Pharma A/S. P.Eriksson: Employee; Zealand Pharma A/S. M.A.Agersnap: Employee; Zealand Pharma A/S.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.